Publications
Publications:
A list of key publications from the Early Phase Cancer Trials Programme at UCL/UCLH
2021:
SARC025 arms 1 and 2: A phase 1 study of the poly(ADP-ribose) polymerase inhibitor niraparib with temozolomide or irinotecan in patients with advanced Ewing sarcoma
| Journal | ACS Journals - Cancer / Volume 127, Issue 8 / p. 1301 -1310 |
| Date | 15 Apr 2021 |
Principal Investigator Clinical Trial | Dr. Sandra Strauss ESP1_SARC025 (ESPIRIT) |
| Authors | Rashmi Chugh, Karla V. Ballman, Lee J. Helman, Shreyaskumar Patel, Jeremy S. Whelan, Brigitte Widemann, Yao Lu, Douglas S. Hawkins, Leo Mascarenhas, John W. Glod, Jiuping Ji, Yiping Zhang, Denise Reinke, Sandra J. Strauss |
| Link: https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.33349 | |
Conference Abstracts
A list of key abstracts presented at conferences from the Early Phase Cancer Trials Programme at UCL/UCLH
2021:
866P - ORCA-2: A phase I study of olaparib in addition to cisplatin-based concurrent chemoradiotherapy for patients with high risk locally advanced (LA) squamous cell carcinoma of the head and neck (HNSCC)
| Conference | ESMO Congress 2021 |
| Date | 16 Sep 2021 |
| Presenter/ Cancer Principal Investigator | Dr. Martin Forster |
| Authors | M. Forster, R. Mendes, T. Guerrero Urbano, M. Evans, M. Lei, V. Spanswick, E. Miles, R. Simões, G. Wheeler, S. Forsyth, L. White |
| Link: ESMO Congress 2021 | |
CT010 - Primary Results of Phase 2 FOENIX-CCA2: The Irreversible FGFR1-4 Inhibitor Futibatinib in Intrahepatic Cholangiocarcinoma (iCCA) with FGFR2 Fusion/Rearrangements
| Conference | AACR Annual Meeting 2021 |
| Date | 11 Apr 2021 |
| Presenter/ Cancer Principal Investigator | Prof. John Bridgewater |
| Author(s) | Lipika Goyal, Funda Meric-Bernstam, Antoine Hollebecque, Chigusa Morizane, Juan W. Valle, Thomas B. Karasic, Thomas A. Abrams, Robin Kate Kelley, Philippe Cassier, Junji Furuse, Heinz-Josef Klümpen, Heung-Moon Chang, Li-Tzong Chen, Yoshito Komatsu, Kunihiro Masuda, Daniel Ahn, Yaohua He, Nital Soni, Karim A. Benhadji, John A. Bridgewater. |
| Link: AACR Annual Meeting 2021 | |
129 Mosunetuzamab In Combination With Lenalidomide Has a Manageable Safety Profile and Encouraging Activity in Patients with Relapsed/Refractory Follicular Lymphoma: Initial Results from a Phase IB Study
| Conference | American Society of Haematolog (ASH) Annual Meeting & Exposition 2021 |
| Date | 11 Dec 2021 |
| Presenter/ Cancer Principal Investigator | Dr. William Townsend |
| Author(s) | Franck Morschhauser, Mark Bishton, Toby A. Eyre, Emmanuel Bachy, Guillaume Cartron, Loïc Ysebaert, Sabela Bobillo, Norma C. Gutierrez, L. Elizabeth Budde, Christopher P. Fox, Andrea Knapp, Manejeh Yaqub, Michael C. Wei, Carol O’Hear, Haocheng Li, Enkhtsetseg Purev, and William Townsend |
| Link: ASH Annual Meeting and Exposition 2021 | |
162 Iberdomide (IBER) in Combination with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Dose-Expansion Phase of the CC-22-MM-001 Trial
| Conference | American Society of Haematolog (ASH) Annual Meeting & Exposition 2021 |
| Date | 11 Dec 2021 |
| Presenter/ Cancer Principal Investigator | Dr. Rakesh Popat |
| Author(s) | Sagar Lonial, Rakesh Popat, Cyrille Hulin, Sundar Jagannath, Albert Oriol, Paul G. Richardson, Thierry Facon, Katja Weisel, Jeremy T. Larsen, Monique C. Minnema, Al-Ola Abdallah, Ashraf Z. Badros, Stefan Knop, Edward A. Stadtmauer, Min Chen, Tuong Vi Nguyen, Alpesh Amin, Elisabeth Kueenburg, Teresa Peluso, Niels W.C.J. van de Donk |
| Link: https://ash.confex.com/ash/2021/webprogram/Paper147704.html | |
4118 Enrolment and Outcomes of Ethnic Minorities with Multiple Myeloma Treated in UK Myeloma Research Alliance (UK-MRA) Clinical Trials over 18 Years
| Conference | American Society of Haematolog (ASH) Annual Meeting & Exposition 2021 |
| Date | 13 Dec 2021 |
| Presentation/ Cancer Principal Investigator | Dr. Rakesh Popat |
| Author(s) | Rakesh Popat, Zoe Craig, Faith E Davies, David Cairns, Catherine Olivier, Gareth J. Morgan, Gordon Cook, Graham H Jackson |
| Link: https://ash.confex.com/ash/2021/webprogram/Paper149148.html | |
2746 Can Patient-Reported Ocular Symptoms Guide Dose Modifications in Patients with Relapsed/Refractory Multiple Myeloma Receiving Belantamab Mafodotin?
| Conference | American Society of Haematolog (ASH) Annual Meeting & Exposition 2021 |
| Date | 12 Dec 2021 |
| Presenter/ Cancer Principal Investigator | Dr. Rakesh Popat |
| Author(s) | Rakesh Popat, Ashraf Z. Badros, Shaji K Kumar, Paula Rodríguez-Otero, Adam D. Cohen, Salomon Manier, Peter M. Voorhees, Francesca Gay, Robert M. Rifkin, Thomas Martin, Ajai Chari, Katja Weisel, Asim V. Farooq, Bennie H. Jeng, Wee Joo Chng, Hans C. Lee, Jesus Berdeja, Vinay Jadhav, Alessandra Tosolini, Laurie Eliason, Antonio Palumbo, Meletios A. Dimopoulos, Sagar Lonial, Suzanne Trudel, Paul G. Richardson, Evangelos Terpos |
| Link: https://ash.confex.com/ash/2021/webprogram/Paper152681.html | |
2479 Glofitamab Plus R-CHOP Induces High Response Rates with Minimal Cytokine Release Syndrome (CRS) in Patients (pts) with Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) and Previously Untreated (1L) Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results from a Dose-Escalation and Safety Run-in Phase Ib Study
| Conference | American Society of Haematolog (ASH) Annual Meeting & Exposition 2021 |
| Date | 12 Dec 2021 |
| Presenter/ Cancer Principal Investigator | Dr. William Townsend |
| Author(s) | Nilanjan Ghosh, William Townsend, Michael Dickinson, Max Topp, Monica Tani, Armando Santoro, Michael Crump, Franck Morschhauser, Steven Le Gouill, Amitkumar Mehta, Anesh Panchal, Chun Wu, Martin Barrett, Kathryn Humphrey, Naseer Qayum, Martin Hutchings |
| Link: https://ash.confex.com/ash/2021/webprogram/Paper147780.html | |
2020:
DREAMM-6: Safety, Tolerability and Clinical Activity of Belantamab Mafodotin (Belamaf) in Combination with Bortezomib/Dexamethasone (BorDex) in Relapsed/Refractory Multiple Myeloma (RRMM)
| Conference | American Society of Haematolog (ASH) Annual Meeting & Exposition 2020 |
| Date | 05/11/2020 |
| Presenter/ Cancer Principal Investigator | Dr. Rakesh Popat |
| Author(s) | Rakesh Popat, Ajay Nooka, Keith Stockerl-Goldstein, Rafat Abonour, Ryan Ramaekers, Amit Khot, Adam Forbes, Cindy Lee, Bradley Augustson, Andrew Spencer, Maria-Victoria Mateos, Bikramjit Chopra, Rachel Rogers, Deborah A Smith, Jacqueline Davidge, Rocio Montes de Oca, Geraldine Ferron-Brady, Anne Yeakey, Mala Talekar, Brandon E. Kremer, Ira Gupta, Hang Quach |
| Link: ASH Annual Meeting and Exposition 2020 | |
Absract CT129: HyPeR: A phase 1, dose escalation and expansion trial of guadecitabine (SGI-110), a second-generation hypomethylating agent in combination with Pembrolizumab (MK3475) in patients with refractory solid tumors
| Conference: | AACR Annual Meeting 2020 |
| Date: | 15/08/2020 |
| Presenter/ Cancer Principal Investigator | Dr. Dionysis Papadatos-Patos |
| Author(s) | Dionysis Papadatos-Pastos; Abhijit Pal; Melek Akay; Malaka Ameratunga; Sanjena Mithra; Joo-Ern Ang; Sofia Levva; Reece Caldwell; Ruth Riisnaes; Mateus Crespo; Wei Yuan; George Seed; Bora Gurel; Ines Figueiredo; Rita Pereira; Susana Miranda; Anna Ferreira; Suzanne Carreira; Claudia Bertan; Chloe Baker; Ricardo Morilla; Robert Brown; Nahal Masrour; Toby Prout; Anna Zachariou; Alison Turner; Mona Parmar; Mark Van de Velde; Ben Jenkins; Christina Yap; Nina Tunariu; Udai Banerji; Juanita Lopez; Anna Minchom; Johann De Bono |
| Link: AACR Annual Meeting 2020 | |
